A Delaware jury has found in favor of Natera in a patent infringement lawsuit against CareDx, awarding the genetic testing company over $96 million in damages. The court ruled that CareDx, a company specializing in transplant diagnostics, infringed upon one of Natera’s patents with the sale of its DNA tests for organ transplant recipients.
This decision comes amidst increasingly ferocious competition in the field of DNA testing technologies. The specific nature of the patent or how the infringement occurred, as well as potential implications for CareDx and the gene testing market at large, are not immediately clear.
For those wishing to delve deeper into this case and its potential impact on the healthcare and biotechnology sectors, the details of the trial provide a glimpse into the inner workings of patent litigation within these rapidly developing fields.